Skip to main content
Clinical Trials/NCT03272516
NCT03272516
Completed
Not Applicable

Mindfulness Based Cognitive Therapy (MBCT) for Primary Care Patients With Mild to Moderate Symptoms of Depression or Anxiety.

University of Iceland2 sites in 1 country120 target enrollmentSeptember 12, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Depression, Anxiety
Sponsor
University of Iceland
Enrollment
120
Locations
2
Primary Endpoint
Symptoms of depression measured with the PHQ-9 questionnaire
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

This study is done to evaluate the effects of Mindfulness Based Cognitive Therapy (MBCT) for primary care patients that have mild to moderate symptoms of depression and anxiety. Half of the study participants will receive treatment as usual (TAU), and the other half will receive TAU plus MBCT. The investigators will be comparing changes in symptoms of depression and anxiety between the groups, and hypothesize that the TAU plus MBCT group will have significantly lower symptoms of depression and anxiety compared to TAU group post-intervention

Detailed Description

Patients that show mild to moderate symptoms of depression and anxiety are common in the primary care setting. These patients are often treated with antidepressant or anxiolytic medication instead of cognitive therapy, which is the first choice of treatment according to clinical guidelines in Iceland. Although these patients are often referred to cognitive therapy, there are long waiting lists for group therapy and personal therapy is expensive. MBCT has been shown to have good effects on people with recurrent depression and on patients suffering from anxiety. Therefore, the investigators main objective is to assess whether MBCT is effective in the primary care setting for patients with mild symptoms of anxiety and depression and compare its effect to TAU.

Registry
clinicaltrials.gov
Start Date
September 12, 2017
End Date
October 21, 2020
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Svala Sigurdardottir

Principal Investigator

University of Iceland

Eligibility Criteria

Inclusion Criteria

  • PHQ-9 and GAD-7 score 5-14 points
  • Age18 - 67
  • No current/recent psychotherapy of any kind other than his/hers physicians therapy( can be taking antidepressants but not in CBT)
  • No regular meditation or yoga practice
  • Not mentally retarded
  • Speaks and understands Icelandic
  • No current substance dependence
  • Not diagnosed with schizophrenic symptoms or bipolar disease that that currently requires treatment
  • Not participating in another mental health study

Exclusion Criteria

  • Age: \<18 and \>67 years old.
  • Severe psychiatric symptoms requiring psychiatric care
  • Risk of suicide
  • Inability to participate in group sessions because of severe substance misuse;
  • Inability to speak and understand Icelandic
  • Current psychotherapy of any kind;
  • Participation in any other psychiatric intervention study;
  • Thyroid disease (if newly diagnosed by the doctor).
  • Score under 5 on both GAD7 and PHQ-9 and score over 14 on either GAD7 or PHQ-
  • One or more of the following ICD-10 psychiatric diagnoses:

Outcomes

Primary Outcomes

Symptoms of depression measured with the PHQ-9 questionnaire

Time Frame: up to 18 months

Comparing scores on the PHQ-9 before and after the intervention as well as, 6 and 18 months after the intervention for both the control group (TAU) and the intervention group (TAU plus MBCT)

Symptoms of anxiety measured with the GAD-7 questionnaire

Time Frame: up to 18 months

Comparing scores on the GAD-7 before and after the intervention as well as 6 and 18 months after the intervention for both the control group (TAU) and the intervention group (TAU plus MBCT)

Secondary Outcomes

  • Subjective well-being measured with the SWEMWBS questionnaire(up to 18 months)
  • Change in use of antidepressants(up to 18 months)
  • Change in use of anxiolytics(up to 18 months)

Study Sites (2)

Loading locations...

Similar Trials